Serum exosomal microRNAs as novel biomarkers for hepatocellular carcinoma

Experimental and Molecular Medicine

Volumn 47, Issue 9, 2015, Pages

  Sohn, Won ^a   Kim, Jonghwa ^a   Kang, So Hee ^a   Yang, Se Ra ^a   Cho, Ju Yeon ^a   Cho, Hyun Chin ^b   Shim, Sang Goon ^b   Paik, Yong Han ^c  

^a Samsung Medical Center   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Sungkyunkwan University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

EXOSOMAL MICRORNA; EXOSOMAL MICRORNA 101; EXOSOMAL MICRORNA 106B; EXOSOMAL MICRORNA 122; EXOSOMAL MICRORNA 18A; EXOSOMAL MICRORNA 195; EXOSOMAL MICRORNA 21; EXOSOMAL MICRORNA 221; EXOSOMAL MICRORNA 222; EXOSOMAL MICRORNA 224; EXOSOMAL MICRORNA 93; MICRORNA; UNCLASSIFIED DRUG; TUMOR MARKER;

ADULT; AGED; ARTICLE; CAENORHABDITIS ELEGANS; CHRONIC HEPATITIS B; CONTROLLED STUDY; EXOSOME; FEASIBILITY STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; WESTERN BLOTTING; BLOOD; CARCINOMA, HEPATOCELLULAR; GENE EXPRESSION PROFILING; GENETICS; LIVER; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; EXOSOMES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED;

EID: 84975321793     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2015.68     Document Type: Article

References (47)

1. Bushati N, Cohen SM. microRNA functions. Annu Rev Cell Dev Biol 2007; 23: 175-205.
2. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
3. Benhamou Y, Di Martino V, Bochet M, Colombet G, Thibault V, Liou A et al. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001; 34: 283-287.
4. Ruan K, Fang X, Ouyang G. MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer Lett 2009; 285: 116-126.
5. Nana-Sinkam SP, Croce CM. Clinical applications for microRNAs in cancer. Clin Pharmacol Ther 2013; 93: 98-104.
6. Borel F, Konstantinova P, Jansen PL. Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol 2012; 56: 1371-1383.
7. Giordano S, Columbano A. MicroRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? Hepatology 2013; 57: 840-847.
8. Lasser C, Exosomal RNA. as biomarkers and the therapeutic potential of exosome vectors. Expert Opin Biol Ther 2012; 12(Suppl 1): S189-S197.
9. Pant S, Hilton H, Burczynski ME. The multifaceted exosome: biogenesis, role in normal and aberrant cellular function, and frontiers for pharmacological and biomarker opportunities. Biochem Pharmacol 2012; 83: 1484-1494.
10. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosomemediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007; 9: 654-659.
11. Lima LG, Chammas R, Monteiro RQ, Moreira ME, Barcinski MA. Tumorderived microvesicles modulate the establishment of metastatic melanoma in a phosphatidylserine-dependent manner. Cancer Lett 2009; 283: 168-175.
12. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 2008; 110: 13-21.
13. Aroldi A, Lampertico P, Montagnino G, Passerini P, Villa M, Campise MR et al. Natural history of hepatitis B and C in renal allograft recipients. Transplantation 2005; 79: 1132-1136.
14. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan E L et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513-10518.
15. Connolly E, Melegari M, Landgraf P, Tchaikovskaya T, Tennant BC, Slagle B L et al. Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype. Am J Pathol 2008; 173: 856-864.
16. Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y et al. MicroRNA-101, downregulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res 2009; 69: 1135-1142.
17. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007; 133: 647-658.
18. Wang Y, Lee AT, Ma JZ, Wang J, Ren J, Yang Y et al. Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J Biol Chem 2008; 283: 13205-13215.
19. Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM, Brackett DJ et al. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res 2008; 14: 419-427.
20. Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, Rebouissou S et al. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 2008; 47: 1955-1963.
21. Huang XH, Wang Q, Chen JS, Fu XH, Chen XL, Chen LZ et al. Bead-based microarray analysis of microRNA expression in hepatocellular carcinoma: miR-338 is downregulated. Hepatol Res 2009; 39: 786-794.
22. Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006; 25: 2537-2545.
23. Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S, Liu C G et al. Cyclin G1 is a target of miR-122a, a microRNA frequently downregulated in human hepatocellular carcinoma. Cancer Res 2007; 67: 6092-6099.
24. Wong QW, Lung RW, Law PT, Lai PB, Chan KY, To KF et al. MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology 2008; 135: 257-269.
25. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408.
26. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008; 3: 1101-1108.
27. Braconi C, Henry JC, Kogure T, Schmittgen T, Patel T. The role of microRNAs in human liver cancers. Semin Oncol 2011; 38: 752-763.
28. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet 2011; 12: 861-874.
29. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99: 15524-15529.
30. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 2012; 4: 143-159.
31. Liu WH, Yeh SH, Lu CC, Yu SL, Chen HY, Lin CY et al. MicroRNA-18a prevents estrogen receptor-alpha expression, promoting proliferation of hepatocellular carcinoma cells. Gastroenterology 2009; 136: 683-693.
32. Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B et al. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci USA 2010; 107: 264-269.
33. Gramantieri L, Fornari F, Ferracin M, Veronese A, Sabbioni S, Calin GA et al. MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin Cancer Res 2009; 15: 5073-5081.
34. Wong QW, Ching AK, Chan AW, Choy KW, To KF, Lai PB et al. MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling. Clin Cancer Res 2010; 16: 867-875.
35. Tsai WC, Hsu PW, Lai TC, Chau GY, Lin CW, Chen CM et al. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 2009; 49: 1571-1582.
36. Xu T, Zhu Y, Xiong Y, Ge Y Y, Yun J P, Zhuang S M. MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology 2009; 50: 113-121.
37. Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol 2011; 45: 355-360.
38. Xu J, Wu C, Che X, Wang L, Yu D, Zhang T et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 2011; 50: 136-142.
39. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol 2013; 200: 373-383.
40. Vlassov AV, Magdaleno S, Setterquist R, Conrad R. Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim Biophys Acta 2012; 1820: 940-948.
41. Tanaka Y, Kamohara H, Kinoshita K, Kurashige J, Ishimoto T, Iwatsuki M et al. Clinical impact of serum exosomal microRNA-21 as a clinical biomarker in human esophageal squamous cell carcinoma. Cancer 2013; 119: 1159-1167.
42. Rabinowits G, Gercel-Taylor C, Day JM, Taylor DD, Kloecker GH. Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer 2009; 10: 42-46.
43. Ma R, Jiang T, Kang X. Circulating microRNAs in cancer: origin, function and application. J Exp Clin Cancer Res 2012; 31: 38.
44. Li J, Wang Y, Yu W, Chen J, Luo J. Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. Biochem Biophys Res Commun 2011; 406: 70-73.
45. Qi P, Cheng SQ, Wang H, Li N, Chen YF, Gao CF. Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS ONE 2011; 6: e28486.
46. Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis 2010; 30: 3-16.
47. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981; 2: 1129-1133.